Roche Acquires TMEM16A Portfolio for CF Treatment

Roche has acquired Enterprise Therapeutics’s TMEM16A potentiator portfolio, which includes ETD002, a therapeutic candidate being evaluated in Phase 1 clinical trials for the treatment of cystic fibrosis (CF). The TMEM16A portfolio is focused on treatments for CF and other severe respiratory disorders characterized by excessive mucus…

NuvoAir Home Platform Classified as Class Im Medical Device

Note: This story was updated Aug. 25, 2020, to clarify that, according to NuvoAir, the regulatory entity in question is the European Medical Device Directive.  The NuvoAir Home platform, NuvoAir’s respiratory support system for patients with lung diseases such as cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF),…

New Inhaled Carrier May Work for CF mRNA Therapy, Mouse Study Finds

An inhaled form of messenger RNA (mRNA) with the potential to safely deliver therapeutics to the lungs of cystic fibrosis (CF) patients has been discovered by researchers at the Massachusetts Institute of Technology (MIT). Researchers developed a type of nanoparticle given as an inhaled mist (nebulizer) that allows the…